Trial reportFrontiers in immunology2024
Evaluation of efficacy and safety of
Trial report in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07505329 (An Intervention Study in Healthy Infants Aged 0-6 Months With Probiotics Lacticaseibacillus Rhamnosus LRa05), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Intervention Study in Healthy Infants Aged 0-6 Months With Probiotics Lacticaseibacillus Rhamnosus LRa05 (LRa05) and Bifidobacterium Animalis Subsp. Lactis BLa80 (BLa80) vs. Placebo, for Promoting Gut Microbiome Development.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness of Lactobacillus-supplemented eradication therapy for Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials.European journal of clinical pharmacology · 2026Pooled it
- Clinical Evidence on the Health Benefits and Safety of Probiotic Lacticaseibacillus rhamnosus: A Systematic Review.Probiotics and antimicrobial proteins · 2026Pooled it
- Impact of continuous care based on multidisciplinary collaboration on the quality of life of patients with colorectal cancer undergoing chemotherapy.Frontiers in medicine · 2026Trial
- Multistrain probiotics alleviate gastrointestinal symptoms during bismuth quadruple therapy forWorld journal of gastroenterology · 2025Trial
- Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026Review
- Probiotics and prebiotics: new treatment strategies for oral potentially malignant disorders and gastrointestinal precancerous lesions.NPJ biofilms and microbiomes · 2025Review
- Exploring the Immunological Role of the Microbial Composition of the Appendix and the Associated Risks of Appendectomies.Journal of personalized medicine · 2025Review
- The role of gut microbiota in diarrhea and its alleviation through microbiota-targeted interventions.Frontiers in microbiology · 2025Review
- Effects of a combination of bifidobacteria quadruple viable bacteria tablets and quadruple therapy on inflammatory response andFrontiers in medicine · 2025Article
- Beyond antibiotics: probiotics as a promising ally againstFrontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aims to evaluate the efficacy of Methods: Results: The LRa05 group exhibited a trend toward higher Conclusion: Although LRa05 did not significantly improve the success rate of Clinical Trial Registration: http://www.chictr.org.cn, identifier ChiCTR2300072220.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.